MOLECULAR MODELING STUDIES OF ALDOSE REDUCTASE INHIBITORS

被引:38
作者
LEE, YS [1 ]
PEARLSTEIN, R [1 ]
KADOR, PF [1 ]
机构
[1] NIH,DIV COMP RES & TECHNOL,BETHESDA,MD 20892
关键词
D O I
10.1021/jm00032a011
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Molecular modeling studies using the AM1 quantum chemical method and a torsional fitting method have been conducted on a series of aldose reductase inhibitors (ARIs) possessing an ionizable group and/or functional group susceptible to nucleophilic attack with the aim of defining the spatial position of AR1 pharmacophores. AM1 quantum chemical calculations were conducted on ARIs possessing only an ionizable group to obtain their optimized geometries. These optimized structures were then superimposed on the model compound spirofluorene-9,5'-imidazolidine-2',4'-dione (17). This superposition study suggests that a negative charge center residing in the vicinity of the 2'-oxygen of the imidazolidine-2',4'-dione ring participates in the binding interactions. In addition, the optimized geometries of ARIs possessing both an ionizable group and an electronegative functional group were superimposed on spirofluorene-9,5'-imidazolidine-2',4'-dione(17). The latter results also suggest the presence of a region where nucleophilic substitution can occur.
引用
收藏
页码:787 / 792
页数:6
相关论文
共 21 条
[1]  
AO S, 1990, CURRENT CONCEPTS ALD, P81
[2]  
ARES JJ, 1986, J MED CHEM, V29, P3834
[3]  
ASPEULAND H, 1967, ACTA ACAD ABO MATH P, V27, P1
[4]   SYNTHESIS AND ALDOSE REDUCTASE INHIBITORY ACTIVITY OF SUBSTITUTED 2-OXOQUINOLINE-1-ACETIC ACID-DERIVATIVES [J].
DERUITER, J ;
BRUBAKER, AN ;
WHITMER, WL ;
STEIN, JL .
JOURNAL OF MEDICINAL CHEMISTRY, 1986, 29 (10) :2024-2028
[5]  
DEWAR MJS, 1985, J AM CHEM SOC, V107, P302
[6]  
DVORNIK D, 1987, ALDOSE REDUCTASE INH, pCH4
[7]   (PYRIMIDINYLOXY)ACETIC ACIDS AND PYRIMIDINEACETIC ACIDS AS A NOVEL CLASS OF ALDOSE REDUCTASE INHIBITORS [J].
ELLINGBOE, J ;
ALESSI, T ;
MILLEN, J ;
SREDY, J ;
KING, A ;
PRUSIEWICZ, C ;
GUZZO, F ;
VANENGEN, D ;
BAGLI, J .
JOURNAL OF MEDICINAL CHEMISTRY, 1990, 33 (10) :2892-2899
[8]  
IKEDA H, 1990, PHARM PROFILE AD547, P97
[9]  
INAGAKI K, 1982, CHEM PHARM BULL, V30, P3244
[10]  
Kador P F, 1987, Prog Clin Biol Res, V232, P353